SCHEMBL1950822

SCHEMBL1950822

CN1Cc2cc(N)ccc2C1(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.35
KDM4E B2RXH2 4/20 0.35
LMNA P02545 2/20 0.35
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 2/20 0.35
NPC1 O15118 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ATAD2 Q6PL18 1/20 0.35
HSD17B3 P37058 1/20 0.35
RAD52 P43351 1/20 0.34
PDK2 Q15119 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
ADRA2C P18825 2/20 0.33
TLR9 Q9NR96 1/20 0.33
NR1H2 P55055 1/20 0.33
GAA P10253 2/20 0.33
CA9 Q16790 1/20 0.33
GFER P55789 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1950736 0.87 KDM4E (0.35) MAPTKDM4ELMNARAB9AALDH1A1
SCHEMBL216072 0.84 ATAD2 (0.41) MAPTKDM4ELMNAALDH1A1ATAD2
SCHEMBL1953079 0.80 DRD1 (0.39) MAPTKDM4ELMNARAD52ADRA2C
SCHEMBL31082076 0.78 BRD4 (0.44) HSD17B3KMT2AMEN1ADRA2C
SCHEMBL20105230 0.78 SRD5A1 (0.40) ALDH1A1
SCHEMBL7656239 0.76 NR1H2 (0.35) MAPTKDM4ELMNARAB9AALDH1A1
SCHEMBL1952621 0.75 ADRA2C (0.39) MAPTKDM4ELMNARAB9AALDH1A1
SCHEMBL29506598 0.75 ADRA2C (0.39) MAPTKDM4ELMNARAB9AALDH1A1
SCHEMBL1952644 0.73 TDP2 (0.44) MAPTLMNARAB9AALDH1A1KMT2A
SCHEMBL11997372 0.72 ALDH1A1 (0.39) MAPTKDM4ELMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718821-B2 Pyridopyrimidinone inhibitors of kinases ABBVIE INC. (US) 2017-08-01 US disclosed
EP-2168966-B1 BICYCLOANILINE DERIVATIVE MSD KK (JP) 2016-09-28 EP disclosed
EP-2168966-B1 BICYCLOANILINE DERIVATIVE MSD KK (JP) 2016-09-28 EP disclosed
EP-2817308-B1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC (US) 2016-09-07 EP disclosed
EP-2681221-B1 TRICYCLIC INHIBITORS OF KINASES ABBVIE INC (US) 2016-05-18 EP disclosed
US-9181239-B2 Pyridopyrimidinone inhibitors of kinases ABBVIE INC. (US) 2015-11-10 US disclosed
EP-2817308-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES AbbVie Inc. (US) 2014-12-31 EP disclosed
EP-2776434-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES Abbvie Inc. (US) 2014-09-17 EP disclosed
US-8710065-B2 Tricyclic inhibitors of kinases ABBVIE INC. (US) 2014-04-29 US disclosed
EP-2681221-A1 TRICYCLIC INHIBITORS OF KINASES AbbVie Inc. (US) 2014-01-08 EP disclosed
US-8436004-B2 Bicycloaniline derivative MSD K.K. (JP) 2013-05-07 US disclosed
US-20130102590-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC (US) 2013-04-25 US disclosed
WO-2013059485-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC. (US) 2013-04-25 WO disclosed
WO-2012161812-A1 TRICYCLIC INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-11-29 WO disclosed
US-20120220572-A1 TRICYCLIC INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-08-30 US disclosed
US-20110135601-A1 BICYCLOANILINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. 2011-06-09 US disclosed
US-20110135601-A1 BICYCLOANILINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. 2011-06-09 US disclosed
US-20110135601-A1 BICYCLOANILINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. 2011-06-09 US disclosed
EP-2168966-A1 BICYCLOANILINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-03-31 EP disclosed
EP-2168966-A1 BICYCLOANILINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102590-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES WEE1, WEE2, CDK1 MAPT 2447/4885KDM4E 585/4885LMNA 3249/4885
US-20120220572-A1 TRICYCLIC INHIBITORS OF KINASES WEE1, WEE2, CDK1 MAPT 2484/4885KDM4E 482/4885LMNA 3229/4885
US-20110135601-A1 BICYCLOANILINE DERIVATIVE WEE1, WEE2, CCNK MAPT 4695/4885KDM4E 1635/4885LMNA 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.